Weight loss peptides: approved drugs, clinical trials, real costs, and country access.
“Weight loss peptides” and “peptides for weight loss” can point to FDA-approved prescription medicines, investigational clinical programs, compounded preparations, and unapproved online products. This guide separates those categories before comparing route, status, evidence, cost, and worldwide access.
Which weight loss peptides can actually be prescribed?
In the United States, WEGOVY, ZEPBOUND, and SAXENDA have product-specific FDA weight-management records. Retatrutide, CagriSema, cagrilintide, Zenagamtide, MariTide, Survodutide, and Eloralintide remain investigational at this check.
Approval, access, and cost are product and country specific. A clinical-trial name on a vial does not create an approved medicine or prove the seller has sponsor material.
Open every FDA product record →Approval belongs to the product record.
Active ingredients appear across brands, indications, compounded preparations, and unapproved offers. The application number resolves the US approval.
WEGOVY
- Route
- Injection and tablets
- Status
- FDA-approved prescription product
The approval belongs to the exact WEGOVY product and label, not every semaglutide offer.
ZEPBOUND
- Route
- Injection
- Status
- FDA-approved prescription product
ZEPBOUND and Mounjaro are different products, and compounded tirzepatide is not FDA approved.
SAXENDA
- Route
- Injection
- Status
- FDA-approved prescription product
The product-specific weight-management label does not transfer to every liraglutide product.
The programs people are searching before approval.
Each row is a development program, not a retail product. Status and evidence can change before any regulator authorizes a final label.
| Program | Strategy | Current evidence lane |
|---|---|---|
| Retatrutide | GIP, GLP-1, and glucagon triple agonist | Phase 3 program reporting results |
| CagriSema | Cagrilintide plus semaglutide | FDA application under review |
| Cagrilintide | Long-acting amylin analogue | Standalone Phase 3 program |
| Zenagamtide / Amycretin | GLP-1 plus amylin receptor agonist | Oral and injected development |
| MariTide | GLP-1 agonism plus GIP antagonism | Monthly Phase 3 program |
| Survodutide | GLP-1 plus glucagon dual agonist | Phase 3 obesity and liver program |
| Eloralintide | Selective amylin receptor agonist | Phase 3 ENLIGHTEN program |
| Mazdutide | GLP-1 plus glucagon dual agonist | China approvals, separate global status |
Check the destination before treating access as global.
These country guides connect each destination with official medicine, pharmacy, seller, safety, and supply routes. A US approval, China approval, sponsor trial, or seller claim does not transfer automatically across borders.
Open all 42 country guides ↗Check one name in one country ↗ An English-language name is not a substitute for local-language research or destination-specific records.
Short answers with the evidence boundary attached.
These answers avoid a cross-trial winner, an invented pharmacy supply, and an ingredient-level approval shortcut.
Which peptides are FDA approved for weight loss?
The current US product-specific records tracked here include WEGOVY, ZEPBOUND, and SAXENDA. The active ingredient alone is not the approval. The exact brand, application number, presentation, labeled population, and current prescribing information define the approved product.
Is Retatrutide approved or available to buy?
Retatrutide remains investigational at this evidence check. A Phase 3 result does not create an FDA-approved product, commercial label, pharmacy price, or authenticated retail supply. Online products using the name are not proven to be Lilly's clinical-trial material.
What is the strongest peptide for weight loss?
There is no defensible single winner across approved and investigational programs. Percentages come from different populations, durations, doses, estimands, and discontinuation rules. Retatrutide's 28.3% Phase 3 efficacy estimate is notable, but it is not a head-to-head verdict over every other program.
Does CagriSema preserve muscle?
That claim is not established. A REDEFINE 1 body-composition subset reported changes in fat mass and lean soft-tissue mass. Lean soft-tissue mass declined, and the measure is not identical to muscle mass. The evidence does not support a simple muscle-preserver label.
Is Amycretin an oral peptide pill?
Zenagamtide is the current name for the program formerly called amycretin. Novo Nordisk is studying both oral and subcutaneous formulations. The early 13.1% oral result came from a small 12-week Phase 1 cohort and does not establish an approved pill, final dose, or superiority.
Can MariTide be taken quarterly?
MariTide's lead efficacy program is monthly. Lower-frequency maintenance research included selected participants who had already lost substantial weight and remained on treatment. That does not establish quarterly starting treatment for everyone or weight maintenance after stopping the drug.
Are these drugs available worldwide?
No ingredient-level answer applies worldwide. Product authorization, prescription rules, pharmacy status, reimbursement, and supply differ by country. Use the country map to open the destination's official medicine and seller records instead of assuming a US or China status transfers globally.
Is Foundayo a weight-loss peptide?
No. FOUNDAYO contains orforglipron, an FDA-approved oral non-peptide small-molecule GLP-1 receptor agonist. It is an important convenience and cost comparator, but molecularly it does not belong in a list of peptide drugs.
Go from category intent to the exact record.
A peptide name is not a treatment recommendation.
This guide organizes product and clinical evidence. It does not determine individual suitability, reproduce administration instructions, or treat an investigational product as available.
For access questions, verify the exact prescription product and seller in the destination's official records and discuss treatment decisions with a licensed clinician.